CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Venus MedTech HangZhou Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Venus MedTech HangZhou Inc
Room 311, 3/F, Block 2, No. 88
Jiangling Road, Binjiang District
HANGZHOU, ZHJ  China Ticker: 25002500
Business Summary
Venus Medtech Hangzhou Inc is a China-based company principally engaged in the research and development, and the manufacture and sale of bioprosthetic heart valves. The Company mainly engages in minimally invasive medical devices and auxiliary instruments and equipment for the treatment of heart valve diseases. The Company provides interventional heart valve devices for valvular heart disease including aortic valve, pulmonic valve, mitral valve and tricuspid valve, a radio frequency ablation system for interventional treatment of HCM, a renal artery denervation ultrasound ablation system for interventional treatment of hypertension and other accessory consumables. The Company's main products include the VenusA-Valve System, VenusA-Plus System, VenusA-Pilot System, VenusP-Valve System, TMVR valve, TTVR valve, valvuloplasty balloons V8/TAV8 and TriGUARD3 Cerebral Embolic Protection Device. The Company mainly conducts its businesses in the domestic market and overseas markets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Ting YukWu 70 12/15/2023 11/1/2018
Chief Financial Officer WangFei 46 1/4/2024 1/4/2024
Executive Director, Vice President of Clinical Medicine MaLiqiao 39 12/15/2023 1/1/2019
6 additional Officers and Directors records available in full report.

Business Names
Business Name
2500
Cardiovalve Ltd.

General Information
Number of Employees: 778 (As of 6/30/2024)
Outstanding Shares: 441,011,443 (As of 6/30/2024)
Stock Exchange: HKG


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, January 30, 2025